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Abstract
Background and Aims Gastrointestinal pathogen panels (GPPs) are increasingly being used for evaluation of diarrhea. The 
impact of these tests on patients with inflammatory bowel diseases (IBD) is unknown. We performed a time-interrupted 
cohort study comparing GPPs and conventional stool evaluation in patients with IBD with diarrhea.
Methods We included 268 consecutive patients with IBD who underwent GPP (BioFire  Diagnostics®) (n = 134) or conven-
tional stool culture and Clostridium difficile polymerase chain reaction testing (n = 134) during suspected IBD flare between 
2012 and 2016. Primary outcome was composite of 30-day IBD-related hospitalization, surgery, or emergency department 
visit; secondary outcome was IBD treatment modification.
Results Overall, 41/134 (30.6%) patients tested positive on GPP (18 C. difficile, 17 other bacterial infections, and 6 viral 
pathogens) versus 14/134 patients (10.4%, all C. difficile) testing positive on conventional testing. Rate of IBD treatment 
modification in response to stool testing was lower in GPP group as compared conventional stool testing group (35.1 vs. 
64.2%, p < 0.01). On multivariate analysis, diagnostic evaluation with GPP was associated with three times higher odds of 
IBD-related hospitalization/surgery/ED visit (95% CI, 1.27–7.14), as compared to conventional stool testing. This negative 
impact was partly mediated by differences in ordering provider specialty, with non-gastroenterologists more likely to order 
GPP as compared to gastroenterologists.
Conclusions In patients with suspected flare of IBD, GPPs have higher pathogen detection rate and lead to lower rate of IBD 
treatment modification. A diagnostic testing strategy based on GPPs is associated with higher hospital-related healthcare 
utilization as compared to conventional stool testing, particularly when utilized by non-gastroenterologists.
Keywords Diagnostic testing · Nucleic acid detection · Overdiagnosis · Complications
Introduction
Gastrointestinal infections present an important conundrum 
in the management of inflammatory bowel disease (IBD). 
Gastrointestinal infections, in particular Clostridium difficile 
(CDI), are common in patients with IBD [1]. In patients Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1062 0-018-5330-y) contains 
supplementary material, which is available to authorized users.
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with known IBD, a flare of IBD may be indistinguishable 
from acute infectious gastroenteritis with patients presenting 
with diarrhea, rectal bleeding, and abdominal pain; moreo-
ver, gastrointestinal infections as well as antibiotic use may 
themselves trigger a flare of IBD [2]. Hence, stool testing 
for gastrointestinal infection is an essential first step in the 
evaluation of an IBD patient presenting with symptoms of a 
flare. Conventionally, stool testing has been performed using 
stool cultures for bacterial pathogens and Clostridium dif-
ficile toxin testing using polymerase chain reaction (PCR).
Over the last 5 years, the United States Food and Drug 
Administration has approved multiplex gastrointestinal 
pathogen panels (GPPs) for evaluation of patients sus-
pected to have acute infectious gastroenteritis [3]. These 
tests simultaneously evaluate for a large number of bacterial, 
viral, and/or parasitic pathogens by detection of microbial 
nucleic acids. Compared to conventional stool tests, GPP 
offers several advantages such as reduced technical exper-
tise, shorter turnaround times, consolidated workflow, and 
increased sensitivity [3, 4]. However, GPP is highly sensitive 
and cannot distinguish between viable, replicating organisms 
that are responsible for disease and non-viable pathogens or 
remnant nucleic acid (colonization); several “pathogens” on 
this panel such as E. coli species (enteropathogenic E. coli 
[EPEC] or enteroaggregative E. coli [EAEC]), adenovirus, 
astrovirus, and Salmonella may be present in the stool of 
asymptomatic individuals, or may be shed for long periods 
of time after resolution of disease [5]. This may be problem-
atic in patients who have underlying chronic gastrointestinal 
diseases such as IBD, wherein positive results may be truly 
pathogenic or may represent overdiagnosis with misattribu-
tion of symptoms to infections, inappropriate use of antibiot-
ics, and delay in IBD-directed therapy.
There has been very limited comparative evaluation 
of clinically relevant outcomes in patients with IBD who 
undergo GPP as compared to conventional stool testing. In a 
study from Mayo Clinic, based on conventional stool exami-
nation, non-CDI bacterial infections were very uncommon 
(< 3%) in patients with IBD and were largely inconsequen-
tial [6]. In contrast, in another referral center study, ~ 14% 
patients with IBD who underwent GPP were positive for 
non-CDI infections, of which one-third were treated with 
antibiotics; these patients were less likely to undergo IBD 
treatment modification as compared to patients who tested 
negative. However, this study did not evaluate downstream 
patient-important consequences of testing and associated 
treatment decisions [7]. Hence, we conducted a retrospec-
tive cohort comparing risk of clinically relevant outcomes 
(30- and 90-day risk of surgery, hospitalization, and/or emer-
gency department [ED] visits) in biologic-exposed patients 
with IBD who underwent conventional stool testing (stool 
culture for bacterial pathogens and C. difficile toxin PCR 
testing) or multiplex GPP for evaluation of suspected IBD 
flare. Our study was designed to evaluate the impact of diag-
nostic approach, rather than focusing on results of specific 
tests, on outcomes of patients [8].
Methods
Study Design
We performed a retrospective cohort study in biologic-
exposed patients with IBD seen and followed at University 
of California San Diego (UCSD). Patients were included if 
they had a definitive diagnosis of IBD (based on clinical his-
tory, endoscopy, radiology, and/or histology), were treated 
with biologic agents any time between January 1, 2012, and 
December 31, 2016, were followed at UCSD for > 6 months, 
and underwent stool testing for suspected symptoms of IBD 
flare (diarrhea, rectal bleeding, and/or abdominal pain). 
This study was approved by the UCSD Institutional Review 
Board (IRB #161914).
Enteric Pathogen Testing
Between 2012 and 2015, infectious evaluation for diarrhea 
was performed exclusively using conventional stool testing 
(stool culture and C difficile PCR). C. difficile PCR test at 
our institution detects C. difficile toxin B gene (tcdB) and is 
an FDA-cleared in vitro diagnostic test that has been modi-
fied with performance characteristics validated by the UC 
San Diego Health System Clinical Laboratories. In Septem-
ber 2015, our institution started using GPP, BioFire FilmAr-
ray GI  Panel® (BioFire Diagnostics, Salt Lake City, UT), for 
both inpatient and outpatient diarrhea evaluation [4]. This 
test detects nucleic acid from 22 pathogens including 13 bac-
teria, 5 viruses, and 4 parasites, including C. difficile genes 
for both toxins A (tcdA) and B (tcdB). The GPP is practi-
cally used by providers in the outpatient setting, emergency 
department, and early inpatient setting; it cannot be ordered 
at our institution for inpatients that have been hospitalized 
greater than 72 h, as by that point, any diarrheal diagnos-
tic testing is focused on C. difficile detection. Processing 
(hands-on) time per run takes approximately 2 min, there is 
no separate extraction required, it results return in approxi-
mately 1 h, and it reports dichotomous results (detected or 
not detected) [3]. Between January 1, 2012, and November 
30, 2016, at UCSD, we performed 862 stool cultures tests 
and 2145 GPPs, in both inpatient and outpatient setting in all 
patients. Approximately 4.2% stool cultures tested positive, 
and ~ 10% C. difficile PCR tests were positive. Of all GPP 
tests performed, overall positivity is 36% (including C. dif-
ficile 15.3%, EPEC 9.5%, EAEC 4.9%, norovirus 5.1%, Shi-
gella/enteroinvasive E. coli 3.4%, and Campylobacter 2.4%).
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Patients who underwent either form of testing during 
an episode suggestive of a flare were included; for patients 
who underwent repeated stool evaluation over the course of 
their follow-up at UCSD, only a single test was included. 
To avoid differential testing bias based on provider pref-
erences, we performed a time-interrupted cohort study in 
which all patients included in the conventional testing arm 
underwent testing between 2012 and 2015 (when that was 
the only evaluation available), and all patients included in 
the GPP testing arm had undergone evaluation between 2015 
and 2016. While providers from 2015 to 2016 could choose 
to order conventional testing, GPP, or both, providers often 
chose only one of the two diagnostic evaluation methods. 
Since the outcomes were defined at a fixed 30- and 90-day 
follow-up, differential length of follow-up in these cohorts 
was inconsequential.
Data Abstraction
We abstracted the following values from the medical 
records: (a) patient characteristics: age, sex, race or ethnic-
ity, body mass index; (b) disease characteristics: IBD type, 
phenotype (based on Montreal classification), disease dura-
tion, disease location, prior bowel resection, hospitalization 
within 6 months prior to presentation, CDI, and/or antibiotic 
use within 12 months prior to presentation; (c) treatment 
characteristics: current biologic and/or immunomodulator 
use, prior biologic use, current steroid use, or use within 
12 months prior to presentation; (d) flare characteristics: 
symptoms at presentation (diarrhea, blood in stool, fever, 
abdominal pain), laboratory variables at presentation (white 
blood cell count, hemoglobin, C-reactive protein, albumin); 
(e) enteric pathogen testing: test type, identified pathogen(s), 
ordering providers (gastroenterologists vs. non-gastroen-
terologists); and (f) outcomes: composite of IBD-related 
surgery, hospitalization, and/or ED visit within 30 days or 
90 days of enteric pathogen testing, IBD treatment modifica-
tion (change in corticosteroids, immunomodulators and/or 
biologic) or initiation of antibiotics following enteric patho-
gen testing.
Outcomes
Primary outcome of interest was rate of IBD-related surgery, 
hospitalization, and/or ED visit within 30 days of enteric 
pathogen testing, regardless of test results. Secondary out-
comes were: (a) IBD-related surgery, hospitalization, and/
or ED visit within 90 days of enteric pathogen testing, (b) 
IBD treatment modification in response to enteric pathogen 
testing (change in corticosteroids, immunomodulators and/
or biologic use), and (c) initiation of antibiotics in response 
to enteric pathogen testing.
We also compared outcomes in patients who tested 
positive versus negative on corresponding enteric patho-
gen testing modality. Subgroup analysis of patients with 
ulcerative colitis or Crohn’s disease was also performed.
Statistical Analysis
We evaluated the association between type of enteric path-
ogen testing and outcomes and covariates using Chi-square 
test or Fisher’s exact test for categorical variables and 
Student’s t test for continuous variables. To evaluate the 
independent association between type of enteric pathogen 
testing and clinical outcomes, we performed multivariable 
logistic regression analysis after adjusting for age, prior 
hospitalization, current biologic and/or steroid use, and 
C-reactive protein. All hypothesis testing was performed 
using a two-sided p value with a statistical significance 
threshold < 0.05. All statistical analyses were performed 
with Stata MP (StataCorp. 2015. Stata Statistical Soft-
ware: Release 14. College Station, TX: StataCorp LP).
Results
Patient Characteristics
We included 268 symptomatic IBD patients (42.5% with 
ulcerative colitis; 57.5% with Crohn’s disease) who under-
went stool testing (50% conventional stool testing; 50% 
GPP) during the study period. Baseline patient, disease, 
treatment, and clinical presentation characteristics are 
summarized (Table 1). Majority of patients presented with 
diarrhea and/or abdominal pain; 27.6% presented with 
rectal bleeding; and 7.8% patients had fever at presenta-
tion. Overall, 6.7% patients had prior CDI in preceding 
12 months. Patients undergoing GPP had longer disease 
duration (median, 9 vs. 6 years, p < 0.01), higher rate of 
prior bowel resection (43 vs. 26%, p < 0.01), and prior 
anti-TNF exposure (99 vs. 69%, p < 0.01), and were more 
likely to be on biologics at time of enteric pathogen test-
ing (76 vs. 51%, p < 0.01). However, these patients who 
underwent GPP testing were less likely to have been hos-
pitalized in the preceding 6 months (16 vs. 35%, p < 0.01), 
received corticosteroid use within 12 months prior (30 vs. 
46%, p = 0.01), though there was no difference in current 
corticosteroid use (19 vs. 24%, p = 0.46). Gastroenterolo-
gists were more likely to order conventional stool testing 
over GPP (61 vs. 39%), whereas non-gastroenterologists 
were more likely to order GPP testing over conventional 
stool testing (62 vs. 38%).
385Digestive Diseases and Sciences (2019) 64:382–390 
1 3
Table 1  Characteristics of 
patients with inflammatory 
bowel diseases who underwent 
enteric pathogen testing 
using either conventional 
stool evaluation or multiplex 
gastrointestinal pathogen panels
Conventional stool 
evaluation (N = 134)
Gastrointestinal pathogen 
panel (N = 134)
p value
Patient characteristics
 Age (years), mean ± SD 38.9 ± 16.1 41.7 ± 16.1 0.16
 Female, n (% total) 74 (55%) 68 (51%) 0.54
Race/ethnicity, n (%)
  White 105 (78%) 97 (72%) 0.03
  Black 5 (4%) 5 (4%)
  Hispanic 15 (11%) 15 (11%)
  Asian 6 (4%) 2 (1%)
  Other 3 (2%) 15 (11%)
 BMI (kg/m2), mean ± SD 24.3 ± 4.9 25.4 ± 6.5 0.13
Disease characteristics
 Duration (years), median (range) 6 (2–13) 9 (5–19) < 0.01
 IBD subtype, n (%)
  Crohn’s disease 79 (59%) 75 (56%) 0.71
  Ulcerative colitis 55 (41%) 59 (44%)
 CD location, n (%)
  L1 10 (12%) 16 (21%) 0.16
  L2 27 (34%) 18 (24%)
  L3 42 (53%) 39 (52%)
  L4 0 (0%) 2 (3%)
 UC location, n (%)
  Pancolitis 28 (51%) 35 (60%) 0.62
  Left-sided 17 (31%) 16 (27%)
  Proctitis 10 (18%) 8 (13%)
 Prior abdominal surgery, n (%) 35 (26%) 57 (43%) < 0.01
  Last 6 m 10 (7.5%) 9 (7%) 1.0
 Prior hospitalization (last 6 m), n (%) 47 (35%) 22 (16%) < 0.01
 Prior antibiotic use (last 12 m), n (%) 37 (28%) 30 (22%) 0.40
 Prior CDI (last 12 m), n (%) 14 (10%) 4 (3%) 0.03
Treatment characteristics
 Prior anti-TNF exposure, n (%) 93 (69%) 133 (99%) < 0.01
 Prior steroid use (last 12 m), n (%) 61 (46%) 40 (30%) 0.01
 Current medication use
  Immunomodulator use, n (%) 78 (58%) 59 (44%) 0.04
  Steroid use, n (%) 32 (24%) 25 (19%) 0.46
  Biologic use, n (%) 68 (51%) 102 (76%) < 0.01
Clinical presentation
 Symptoms at presentation, n (%)
  Diarrhea 115 (86%) 100 (75%) 0.03
  Blood in stool 38 (28%) 36 (27%) 0.89
  Fever 11 (8%) 10 (7%) 1.0
  Abdominal pain 81 (60%) 95 (71%) 0.09
 Labs at presentation
  WBC (1000/mm3), median (range) 8.1 (6.5–10.8) 8.2 (6.7–11.1) 0.59
  Hemoglobin (gm/dL), median (range) 12.8 (11.6–13.8) 13.2 (11.4–14.5) 0.41
  C-reactive protein (mg/dL), median (range) 0.8 (0.2–3.8) 1.0 (0.2–3.1) 0.77
  Albumin (g/dL), median (range) 4.1 (3.7–4.5) 3.9 (3.7–4.4) 0.28
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Enteric Pathogen Testing
Overall, 41/134 (30.6%) patients tested positive using 
GPPs, with 51 total organisms identified. The most common 
enteric pathogens detected by GPP were E. coli species (19, 
14.2%; mainly enteropathogenic E. coli [EPEC] or entero-
aggregative E. coli [EAEC]) and CDI (18, 13.4%). Other 
pathogens detected included Campylobacter, Salmonella, 
Yersinia, Plesiomonas, Shigella, norovirus, rotavirus, and 
adenovirus (Table 2). Eight (6.0%) patients were noted to 
have co-infections, with two or more detected pathogens. 
Overall, these GPP positivity rates were comparable to rates 
observed institution-wide regardless of underlying disease 
(36%). Patients undergoing GPP did not undergo concomi-
tant conventional stool testing. In contrast, 14/134 (10.4%) 
patients undergoing conventional stool testing had positive 
tests with 14 total organisms identified, all of which were 
CDI; no cases of non-CDI bacterial pathogens were identi-
fied on conventional stool culture. This was also comparable 
to overall institution-wide C. difficile PCR positivity (10%) 
and stool culture positivity (4.2%).
Impact of Enteric Pathogen Testing on Clinical 
Outcomes
Primary Outcome
Overall, 24 (18%) patients underwent GPP testing under-
went IBD-related surgery, hospitalization, and/or ED visit 
within 30 days of testing, as compared to 20 (15%) patients 
who underwent conventional stool testing (Table 3). Similar 
results were obtained when evaluating 90-day rates of IBD-
related surgery, hospitalization, and/or ED visit (Table 3), 
and in patients with ulcerative colitis and Crohn’s disease 
(eTable 1 and 2). On multivariable logistic regression, after 
adjusting for age, prior hospitalization, current biologic and/
or steroid use, and C-reactive protein, diagnostic evaluation 
with GPP was associated with three times higher odds of 
IBD-related hospitalization/surgery/ED visit within 30 days 
of testing (OR, 3.03; 95% CI, 1.27–7.14), as compared to 
conventional stool testing (Table 4). Besides enteric patho-
gen testing modality, current corticosteroid use and high 
C-reactive protein were associated with increased risk of 
outcomes, whereas current biologic use was protective 
against hospitalization-related healthcare utilization.
Table 1  (continued)
Bold values are statistical significance (p < 0.05)
BMI Body mass index, CD Crohn’s disease, CDI Clostridium difficile infection, IBD inflammatory bowel 
diseases, TNF tumor necrosis factor, UC ulcerative colitis and WBC white blood cell
Table 2  Identification of enteric pathogens in patients with IBD, 
detected using conventional stool testing or gastrointestinal pathogen 
panels
CDI Clostridium difficile infection, EAEC enteroaggregative E. coli, 
EPEC enteropathogenic E. coli and ETEC enterotoxigenic E. coli
Conventional stool 
evaluation (N = 134)
Gastrointestinal 
pathogen panel 
(N = 134)
Positive test, n (%) 14/134 (10%) 41/134 (31%)
Total # organisms identi-
fied
14 51
Bacteria, n 14 42
CDI 14/14 18/51
Non-CDI bacteria 0/14 24/51
 Escherichia coli species 0 19
  EAEC 6
  EPEC 11
  ETEC 2
 Campylobacter 0 1
 Salmonella 0 1
 Yersinia 1
 Plesiomonas 1
 Shigella 1
Viral, n 0/14 9/51
 Norovirus 6
 Rotavirus 2
 Adenovirus 1
Parasites, n 0 0
Co-infections, n 0 8
Treated with antibiotics,  n 26 35
 CDI 14 15
 Non-CDI bacteria 0 12
 Alternative indication 12 8
Conventional stool 
evaluation (N = 134)
Gastrointestinal pathogen 
panel (N = 134)
p value
 Ordering provider
  Gastroenterologists 88 (66%) 57 (43%) 0.01
  Non-gastroenterologists 46 (34%) 77 (57%)
   Emergency department 6 25
   Inpatient hospitalization 39 51
   Medicine clinic 1 1
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To assess whether impact of GPP testing on outcomes 
may be influenced by ordering provider, we added order-
ing provider to the multivariable model (Table 4). Non-
gastroenterologist as ordering provider was independently 
associated with higher odds of IBD-related hospitalization/
surgery/ED visit within 30 days of testing (OR, 3.73; 95% 
CI, 1.34–10.36), whereas the independent impact of GPP 
testing was not significant.
Secondary Outcomes
IBD Treatment Modification Patients who underwent GPP 
testing were significantly less likely to undergo IBD treat-
ment modification in response enteric pathogen testing as 
compared to patients who underwent conventional stool test-
ing (35 vs. 64%, p < 0.01). Patients undergoing GPP testing 
were less likely to have addition of corticosteroids, change 
Table 3  Association between enteric pathogen testing and 30- and 90-days risk of hospitalization-related healthcare utilization and change in 
IBD management
Bold values are statistical significance (p < 0.05)
ED Emergency department, IBD inflammatory bowel diseases
Conventional stool evaluation 
(N = 134)
Gastrointestinal pathogen panel 
(N = 134)
p value
Primary outcome (30 day)
 Hospitalization-related healthcare utilization (30 day) 20 (15%) 24 (18%) 0.51
 ED visit (30 day) 20 (15%) 24 (18%) 0.51
 Hospitalization (30 day) 18 (13%) 19 (14%) 0.86
 Surgery (30 day) 9 (7%) 8 (6%) 0.80
Sensitivity analysis (90 day)
 Hospitalization-related healthcare utilization (90 day) 30 (22%) 34 (25%) 0.57
 ED visit (90 day) 30 (22%) 34 (25%) 0.57
 Hospitalization (90 day) 27 (20%) 27 (20%) 1.0
 Surgery (90 day) 11 (8%) 8 (6%) 0.48
Secondary outcome
 Change in IBD 86 (64%) 47 (35%) < 0.01
 Management, n (%)
  Addition of corticosteroids 46 (34%) 27 (20%) 0.03
  Change in immunomodulators 27 (20%) 14 (10%) < 0.01
  Change in biologics 56 (42%) 21 (16%) < 0.01
Table 4  Factors associated 
with increased risk of 30 day 
of hospitalization-related 
healthcare utilization based on 
multivariate logistic regression 
analysis adjusting for (A) age, 
prior
Bold values are statistical significance (p < 0.05)
a Multivariate model inclusive of: age and hospitalization within last 6 months
Variables Multivariatea
OR (95% CI) p value
Current steroid use 3.09 (1.32–7.21) 0.009
Current biologic use 0.28 (0.12–0.65) 0.003
C-reactive protein (per 1 mg/dl) 1.11 (1.04–1.20) 0.003
GI pathogen panel versus conventional stool testing 3.03 (1.27–7.14) 0.013
Adding ordering provider as an additional variable
 Current steroid use 2.89 (1.21–6.89) 0.016
 Current biologic use 0.33 (0.14–0.78) 0.011
 C-reactive protein (per 1 mg/dl) 1.08 (1.00–1.16) 0.048
 GI pathogen panel versus conventional stool testing 2.00 (0.81–4.95) 0.132
 Non-GI providers versus GI providers 3.73 (1.34–10.36) 0.011
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in biologics as well as immunomodulator use (Table  3). 
These results were stable in subgroup analyses in patients 
with ulcerative colitis or Crohn’s disease (eTable 1 and 2).
Antibiotic Use Thirty-five (26.1%) patients who underwent 
GPP received antibiotics compared to 26 (19.4%) patients 
undergoing conventional stool testing (p = 0.24). Among 
GPP-positive patients, 15 (42.9%) received antibiotics for 
CDI, 12 (34.3%) received antibiotics for non-CDI bacteria, 
and 8 (22.9%) patients received antibiotics for alternative 
indications (suspected pouchitis, perianal fistula, suspected 
intra-abdominal abscess, and/or suspected gastrointestinal 
infection); 3 patients detected to have CDI on GPP test-
ing did not receive antibiotics. Among patients who were 
positive on conventional stool testing, 14 (53.8%) patients 
received treatment for CDI and 12 (46.2%) received antibi-
otics for alternative indications.
Enteric Pathogen Test Positivity Versus Negativity
There was no significant difference in 30- or 90-day rates 
of IBD-related surgery, hospitalization, and/or ED visit 
between patients who tested positive or negative on GPP, 
and in patients who tested positive or negative on conven-
tional stool testing (eTable 3). Numerically, rate of addition 
of corticosteroids was lower in patients who tested positive 
versus negative on GPP testing (24 vs. 12%, p = 0.13). On 
multivariate logistic regression among a subset of patients 
who underwent GPP testing, test positivity versus negativity 
did not significantly affect risk of 30-day hospitalization-
related healthcare utilization (data not shown).
Discussion
In this time-interrupted, retrospective cohort study of 268 
patients with IBD, who underwent either conventional 
stool testing using stool culture and C. difficile toxin PCR 
testing or multiplex GPP for symptoms suggestive of IBD 
flare, we made several key observations. First, enteric 
pathogen positivity was almost three times higher with 
GPP testing than conventional stool testing in patients with 
IBD; this rate aligns with overall GPP test positivity at 
our center across all patient populations. Overall rates of 
CDI detection were comparable between both tests, but 
GPP identified 19 additional patients as having non-CDI 
bacterial infections, primarily E. coli species (EPEC and 
EAEC), and 4 patients with viral pathogens; conventional 
stool cultures were negative for non-CDI bacteria. Sec-
ond, after adjusting for important covariates, patients who 
underwent GPP testing had three times higher odds of hav-
ing IBD-related surgery, hospitalization, or ED visit within 
30 days of testing, as compared to patients who underwent 
conventional stool testing. This effect was partly mediated 
by ordering providers. Patients who underwent stool test-
ing by non-gastroenterologists versus gastroenterologists 
experienced higher rates of adverse outcomes. This may 
be related to challenges in test interpretation and action by 
non-gastroenterologists, rather than actual test findings. 
This is apparently based on our observation that patients 
undergoing GPP testing were more likely to receive anti-
biotics, and less likely to have their IBD-related medica-
tions changed, as compared to patients who underwent 
conventional stool testing.
By specifically focusing on impact of a diagnostic 
approach (GPP vs. conventional stool testing), rather than 
focusing on test results, on patient-important outcomes, 
we are able to directly inform clinical practice. Our find-
ings suggest that GPP testing to rule out infections in IBD 
patients presenting with symptoms suggestive of flare is 
associated with adverse patient outcomes with higher rates 
of hospitalization-related healthcare utilization. We hypoth-
esize that higher enteric infection positivity on GPP test-
ing leads to misattribution of IBD symptoms to infections 
especially by non-gastroenterologists, and consequent delay 
in IBD-related treated modification and/or excessive use of 
antibiotics resulting in higher rates of ED visit, hospitaliza-
tion, and/or surgery. Based on these findings, GPP testing in 
patients with IBD, especially when applied by non-gastro-
enterologists, likely represents low-value care with potential 
for harm. As such, limiting diagnostic testing to C. difficile 
evaluation may be most appropriate at this time due to its 
clinical significance within this population.
GPPs were approved by the FDA for rapid and simul-
taneous detection of multiple gastrointestinal pathogens 
simultaneously in patients with signs and symptoms sug-
gestive of gastrointestinal infections [4, 5]. While several 
cross-sectional studies have confirmed higher sensitivity 
of these tests, there has been very limited evaluation of 
downstream consequences of GPP testing on clinically 
relevant outcomes. Concerns regarding misattribution of 
symptoms or misdiagnosis of infection in patients with 
asymptomatic colonization as well as healthcare provider 
confusion of interpretation of test results (such as EPEC 
or EAEC positivity, detection of multiple pathogens) with 
broad implementation of these tests have been raised [3, 
4]. In hospitalized patients, inappropriately treating GPP-
positive asymptomatic patients with colonization can lead 
to unnecessary patient isolation, longer length of stay, poor 
antibiotic stewardship, and institutional penalties for artifi-
cially high infectious diarrhea rates. Similar to IBD, over-
reliance on GPP testing may potentially delay diagnosis 
and treatment of other non-infectious diarrhea that may 
be seen in other immunocompromised patients (e.g., post-
chemotherapy), organ transplant recipients, patients with 
human immunodeficiency virus, etc.
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Patients with IBD represent a unique population when 
using GPPs based on the overlap in symptoms between gas-
trointestinal infections and IBD flare, dysbiosis with higher 
baseline prevalence of specific and potentially pathogenic 
E. coli species, such as adherent-invasive E. coli in patients 
with IBD, as well as potential for IBD flare due to potentially 
pathogenic bacteria or subsequent antibiotic exposure [2, 9]. 
There has been limited evaluation of GPPs in patients with 
IBD. In a single-center study, Axelrad and colleagues evalu-
ated outcomes in 214 symptomatic patients with IBD who 
underwent 295 GPP using BioFire Film Array and C. dif-
ficile PCR testing [7]. In their cohort, 12.9% tested positive 
for CDI, and 13.9% tested positive on the GPP for other non-
CDI pathogens (primarily E. coli species), comparable to our 
cohort. Approximately 50% patients who tested positive for 
non-CDI bacterial pathogens were treated with antibiotics, 
as compared to 34.3% in our cohort. Comparing patients 
with positive test results on GPP for non-CDI pathogens 
and negative tests, they did not observe any significant dif-
ferences in rates of hospitalization or surgery, though rate of 
IBD treatment modification was higher in those with nega-
tive results. In another single-center study of 131 patients 
with IBD (89% inpatients, 47% on biologics, 88% with 
objective evidence of active IBD) published only in abstract 
form, by Limsrivilai and colleagues, ~ 30% tested positive 
for enteric pathogens on GPP. GPP positivity was signifi-
cantly higher in patients with active IBD-related inflamma-
tion (33 vs. 6% in patients without active IBD) [10]. They 
observed lower rates of escalation of IBD-related therapy 
and surgery in the short term in those who tested positive on 
GPP, as compared to those who tested negative, interpreting 
that short-term course of IBD may be more benign in those 
who test positive on GPP as compared to those who test neg-
ative. However, it is unclear whether this represents in-hos-
pital outcomes or longer-term outcomes, and whether this 
may be due to a diagnostic dilemma that treating clinicians 
faced, resulting in potential delay in IBD treatment modi-
fication in this retrospective study. In contrast, in a recent 
study from Mayo Clinic using conventional stool testing in 
IBD patients presenting with flare, rate of non-CDI bacterial 
infections was very low (< 3%) and did not influence disease 
course over 1 year, as compared to IBD patients who tested 
negative for infection or in patients with CDI; similar to this 
study, conventional stool testing in our study did not identify 
a single non-CDI pathogen [6]. Furthermore, a recent study 
from Columbia University Medical Center using GPP test-
ing in IBD patients presenting with flare showed that GPP-
positive patients treated with antibiotics for non-CDI had no 
difference in outcomes at median follow-up of 10.5 months 
compared to untreated GPP-positive patients for non-CDI 
[11]. While further studies assessing outcomes for non-CDI 
in IBD patients are needed, currently a C. difficile toxin PCR 
only diagnostic strategy and/or increasing scrutiny prior to 
prescribing antibiotics for a positive GPP test is warranted. 
To our knowledge, ours is the first study that directly com-
pares patient outcomes in patients who underwent GPP test-
ing versus those who underwent conventional stool testing. 
GPP testing, regardless of test results, was associated with 
higher hospitalization-related healthcare utilization, along 
with lower rates of IBD treatment modification.
Our study has several limitations, intrinsic to its retro-
spective design. First, a causal association between GPP 
testing and adverse patient outcomes cannot be established. 
This observation is likely multifactorial, with final decisions 
on IBD management and stool testing interpretation made 
based on case-by-case basis by treating physicians, with lit-
tle evidence-based guidance. We were unable to explicitly 
test our hypothesis that delay in modification of IBD-related 
therapies directly contributed to increased healthcare utiliza-
tion. Second, we designed our study to evaluate the impact 
of diagnostic approach, rather than focusing on results of 
specific tests, on outcomes of patients, as is recommended 
in evaluating quality of evidence supporting diagnostic tests 
[8]. Our study was not powered to detect differences in out-
comes in patients with positive or negative results on GPP 
testing; rather, ours was a convenience sample of biologic-
exposed patients with IBD seen and followed at a tertiary 
center over a 5-year period over which we transitioned from 
conventional stool testing to GPP. To maintain independ-
ence of individual subjects, we counted each patient only 
once, though most patients expectedly underwent multiple 
stool tests. Third, simultaneous GPP and CDI testing for 
toxin was not performed. While there has been no study to 
assess diagnostic performance of GPP against “gold stand-
ard” (i.e., stool culture for bacterial pathogens, etc.) among 
IBD patients, not performing concomitant stool testing with 
GPP and conventional methods prevents the ability to accu-
rately determine whether positivity on GPP was indicative 
of active infection. Fourth, our study population included 
a mix of outpatients and inpatients, seen in multiple differ-
ent settings such as a primary care clinic, gastroenterology 
clinic, a specialized IBD clinic, ED or inpatient hospitali-
zation with threshold and experience for testing likely dif-
ferent between providers in each setting. Fifth, providers 
could choose to order conventional testing, GPP, or both as 
diagnostic testing was not randomized from 2015 to 2016. 
As such, selection bias could have occurred if certain pro-
viders preferentially opted for one testing method. However, 
there is low suspicion for significant differences in patient 
or disease characteristics for IBD patients undergoing either 
test in this time period.
In conclusion, based on a comparative retrospective 
cohort study in biologic-exposed patients with IBD present-
ing with symptoms suggestive of IBD flare, GPP testing is 
associated with increased risk of 30-day IBD-related ED 
visit, hospitalization, or surgery, higher rate of antibiotic 
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prescription and lower rate of IBD-related treatment modi-
fication. GPP tests were more likely to be performed by non-
gastroenterologists, suggesting that interpretation and down-
stream actions by non-gastroenterologists may contribute 
to adverse outcomes seen in these patients. We recommend 
that positive test results on GPPs should be interpreted cau-
tiously, with confirmation of non-CDI bacterial pathogens 
with stool culture where possible, before attributing symp-
toms to infection, rather than underlying IBD. This should 
not delay potential modification of IBD-directed therapy, 
which would be required in a majority of patients. Addition-
ally, due to low rate of non-CDI bacterial culture positivity, 
conventional stool testing in IBD patients may be limited to 
C. difficile toxin PCR. Prospective studies directly evalu-
ating the impact of GPP testing in patients with IBD are 
warranted, with assessment of etiologic predictive value of 
tests [12].
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